Palisade Bio的动态

Obesity-related pathophysiological changes can substantially influence a drug’s pharmacological profile, making early investigation important. However, these pathophysiological changes make it difficult to consider obese individuals as healthy volunteers for early phase trials. Here, IQVIA’s H. David Duque, MD, CPI, examines critical considerations for optimizing drug development among obese individuals. https://bit.ly/461vY5L #clinicaltrials #drugdevelopment

Obesity-related pathophysiological changes can substantially influence a drug’s pharmacological profile, making early investigation important. However, these pathophysiological changes make it difficult to consider obese individuals as healthy volunteers for early phase trials. Here, IQVIA’s H. David Duque, MD, CPI, examines critical considerations for optimizing drug development among obese individuals. https://bit.ly/40Csxlc #obesity #clinicaltrials #drugdevelopment

?? ???????????????? ?????????????? ???????????????????????? ?????? ?????? ?????????????? ?????? ?????????????????? ???????????????????? ??????????! ?? We’re excited to welcome David Tingley, Founder of Olio Labs (YC23), as a panellist on "Exploring the Pros and Cons of Different GLP-1 Drug Combinations" ???? David will share his expertise on: ?? ?????????????????? ??????-?? ???????? ????????????????????????: Gain insights on GIP agonism vs. antagonism—unpacking the unique advantages and potential challenges of each approach. ?? ???????????????? ???????? ???????? ????????: Explore the latest data on efficacy, safety, and patient outcomes to understand how each drug combination performs in real-world settings. ?? ???????????? ???? ?????????????????? ??????????????????: See how these drug combinations are shaping the future of obesity treatment and influencing broader metabolic health strategies. ?? ???????? ???? ???? ???????????????? ?????? ???? ???????????? for a deep dive into the latest in GLP-1 innovation, with insights from industry experts like David Tingley. Register Now! https://lnkd.in/edmGq6qW #GLP1Innovation #ObesityTreatment #MetabolicHealth #HealthcareLeadership

The drug semaglutide and its contemporaries, often referred colloquially by patients as "ozempic", represents a massive sea change in weight loss management. So we wanted to ask our physicians what they think of these SLG-1RAs, both the benefits and challenges. So we did a survey, and some of the data is quite eye-opening. If you're interested in these drugs and what physicians think about them, check out our full survey results here: https://lnkd.in/gQwYR5xv

Collaboration in action! Check out our latest case study to see how teamwork made the dream work in delivering a comprehensive First in Human healthy volunteer trial. From safety and tolerability to pharmacokinetics, pharmacodynamics, and cognitive function assessment, this three-part study is a testament to the power of effective stakeholder collaboration. Don't miss out on the details! https://lnkd.in/ed3FgcMZ

Join us for part 1 of a 2-part webinar focusing on the value of patient-centric blood sampling for the determination of pharmacokinetics in clinical trials; May 16, 12 pm ET: https://bit.ly/4aZu2ML

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100% of CT-388 treated participants achieved >5% weight l... https://lnkd.in/eXp6psK5 #BioTech #science

Renal & Hepatic Impairment PK studies - Interesting dimension of Clinical Trials requiring special knowledge and consideration!

Discover the power of patient-centric sampling in clinical trials! Join our upcoming 2 parts webinar to explore real-world case studies showcasing its applications in #PK assessment. Don’t miss out of this educational opportunity. Register now! #clinicaltrials #DCT #innovation #patientcentricsampling #ASCPTwebinar

Pharmacokinetic-guided dosing appeared feasible for individualizing factor concentrate therapies in patients with hemophilia A or B, according to Tine Goedhart of Erasmus MC et al in Research and Practice Thrombosis and Haemostasis. Find the analysis here: https://lnkd.in/eskTNAhh